Atreca, Inc.

Atreca, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. If you are interested in becoming part of the Atreca team, our open positions can be found at: http://www.atreca.com/careers/

Company Details

Employees
17
Founded
-
Address
South San Francisco, Ca 94080, Us
Phone
6505952618
Email
in****@****eca.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
atreca.com
HQ
South San Francisco, Ca
Looking for a particular Atreca, Inc. employee's phone or email?

Atreca, Inc. Questions

News

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome - GlobeNewswire

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome GlobeNewswire

Atreca downsizes again to focus on antibody-drug conjugate programmes - Clinical Trials Arena

Atreca downsizes again to focus on antibody-drug conjugate programmes Clinical Trials Arena

Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors - Yahoo Finance

Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors Yahoo Finance

Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101 - PNAS

Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101 PNAS

Immunome Announces Completion of Purchase of Assets from Atreca - Business Wire

Immunome Announces Completion of Purchase of Assets from Atreca Business Wire

Atreca, facing Q1 funding cliff edge, cuts head count by 40% for 2nd time in 3 months - Fierce Biotech

Atreca, facing Q1 funding cliff edge, cuts head count by 40% for 2nd time in 3 months Fierce Biotech

Atreca CEO acquires preferred stock for $0.01 - Investing.com

Atreca CEO acquires preferred stock for $0.01 Investing.com

Their company died. Their antimalarial drug lives on — with hopes of saving millions of lives - The Business Journals

Their company died. Their antimalarial drug lives on — with hopes of saving millions of lives The Business Journals

What You Need To Know About Atreca, Inc.'s (NASDAQ:BCEL) Investor Composition - Nasdaq

What You Need To Know About Atreca, Inc.'s (NASDAQ:BCEL) Investor Composition Nasdaq

Atreca Announces Expansion of Preclinical Pipeline - GlobeNewswire

Atreca Announces Expansion of Preclinical Pipeline GlobeNewswire

Startups on the menu: Atreca - Nature

Startups on the menu: Atreca Nature

5 Top NASDAQ Biotech and Pharma Stocks: Atreca Climbs 45 Percent - Investing News Network

5 Top NASDAQ Biotech and Pharma Stocks: Atreca Climbs 45 Percent Investing News Network

Former Big Pharma darling Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs - Fierce Biotech

Former Big Pharma darling Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs Fierce Biotech

Immunome to buy assets from California biotech company - The Business Journals

Immunome to buy assets from California biotech company The Business Journals

Atreca Announces Pricing of Initial Public Offering - GlobeNewswire

Atreca Announces Pricing of Initial Public Offering GlobeNewswire

Oncology biotech Atreca pulled into industry’s layoff whirlpool, cuts 25% of staff - Fierce Biotech

Oncology biotech Atreca pulled into industry’s layoff whirlpool, cuts 25% of staff Fierce Biotech

Mid-Peninsula project rode biotech's boom. Now it's showing how to survive the bust - San Francisco Business Times - The Business Journals

Mid-Peninsula project rode biotech's boom. Now it's showing how to survive the bust - San Francisco Business Times The Business Journals

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody - Fierce Biotech

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody Fierce Biotech

Atreca bags $125M as solid tumor trial comes into view - Fierce Biotech

Atreca bags $125M as solid tumor trial comes into view Fierce Biotech

Biotechs shed dead wood from pipelines amid cash crunch and disappointing data - Fierce Biotech

Biotechs shed dead wood from pipelines amid cash crunch and disappointing data Fierce Biotech

Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive

Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff PharmaLive

Atreca (BCEL) Stock Price, News & Analysis - MarketBeat

Atreca (BCEL) Stock Price, News & Analysis MarketBeat

News | Silicon Valley Biotech Company Axes Deal for Alexandria-Owned HQ - CoStar

News | Silicon Valley Biotech Company Axes Deal for Alexandria-Owned HQ CoStar

Atreca Is Doing More Than Just Creating A Buzz At BIO CEO 2018 - Life Science Leader

Atreca Is Doing More Than Just Creating A Buzz At BIO CEO 2018 Life Science Leader

Cancer biotech Atreca prices IPO at $17 midpoint - Nasdaq

Cancer biotech Atreca prices IPO at $17 midpoint Nasdaq

Top Atreca, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant